financingExeVir receives EIB risk finance for multiple COVID-19 nanobodyLatest NewsWith the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012. Read more 9 January 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/ExeVir_EIB-jpg.jpeg 371 602 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-01-09 11:54:562024-07-15 13:11:58ExeVir receives EIB risk finance for multiple COVID-19 nanobody